About Enlivex Pharmaceuticals
Enlivex Pharmaceuticals is a company based in Jerusalem (Israel) founded in 2005.. Enlivex Pharmaceuticals has raised $7 million across 4 funding rounds from investors including Korea Investment Holdings and Hadasit. The company has 36 employees as of December 31, 2024. Enlivex Pharmaceuticals offers products and services including Allocetra. Enlivex Pharmaceuticals operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Jerusalem, Israel
- Employees 36 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Enlivex Therapeutics Ltd.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-15.01 M48.35as on Dec 31, 2024
-
EBITDA
$-14.99 M37.78as on Dec 31, 2024
-
Total Equity Funding
$7 M (USD)
in 4 rounds
-
Latest Funding Round
$212 M (USD), Post-IPO
Nov 24, 2025
-
Investors
Korea Investment Holdings
& 1 more
-
Employee Count
36
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Enlivex Pharmaceuticals
Enlivex Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ENLV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Enlivex Pharmaceuticals
Enlivex Pharmaceuticals offers a comprehensive portfolio of products and services, including Allocetra. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Off-the-shelf therapy for treating inflammatory diseases via clinical applications
Funding Insights of Enlivex Pharmaceuticals
Enlivex Pharmaceuticals has successfully raised a total of $7M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $212 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $212.0M
-
First Round
First Round
(18 May 2014)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Post-IPO - Enlivex Pharmaceuticals | Valuation |
investors |
|
| Apr, 2019 | Amount | Post-IPO - Enlivex Pharmaceuticals | Valuation |
investors |
|
| Sep, 2017 | Amount | Post-IPO - Enlivex Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enlivex Pharmaceuticals
Enlivex Pharmaceuticals has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Korea Investment Holdings and Hadasit. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment holding firm established in Seoul in 2003.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enlivex Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enlivex Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enlivex Pharmaceuticals Comparisons
Competitors of Enlivex Pharmaceuticals
Enlivex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enlivex Pharmaceuticals
Frequently Asked Questions about Enlivex Pharmaceuticals
When was Enlivex Pharmaceuticals founded?
Enlivex Pharmaceuticals was founded in 2005 and raised its 1st funding round 9 years after it was founded.
Where is Enlivex Pharmaceuticals located?
Enlivex Pharmaceuticals is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
Who is the current CEO of Enlivex Pharmaceuticals?
Oren Hershkovitz is the current CEO of Enlivex Pharmaceuticals.
Is Enlivex Pharmaceuticals a funded company?
Enlivex Pharmaceuticals is a funded company, having raised a total of $7M across 4 funding rounds to date. The company's 1st funding round was a Post-IPO of $8M, raised on May 18, 2014.
How many employees does Enlivex Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at Enlivex Pharmaceuticals is 36.
What does Enlivex Pharmaceuticals do?
Enlivex Pharmaceuticals, a cell immunotherapy company, is developing an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions. Its clinical development programs focus on GvHD (graft versus host disease), CAR-T, and autoimmune diseases; Allocetra, has been developed for the prevention of acute GvHD (Phase 23), particularly severe, or high-grade, acute GvHD (orphan drug designation); Allocetra consists of retrieving a blood sample from the patient or a matched donor, treating it at the cellular level to generate an early apoptotic cell population undergoing apoptosis and injecting it into the patient; Enlivex is also examining the potential for collaborating with leading CAR-T companies in clinical studies to evaluate the efficacy and side effect profile of CAR-T treatments for a variety of cancer-related clinical indications, such as blood cancers and solid tumors.
Who are the top competitors of Enlivex Pharmaceuticals?
Enlivex Pharmaceuticals's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
What products or services does Enlivex Pharmaceuticals offer?
Enlivex Pharmaceuticals offers Allocetra.
Is Enlivex Pharmaceuticals publicly traded?
Yes, Enlivex Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ENLV.
Who are Enlivex Pharmaceuticals's investors?
Enlivex Pharmaceuticals has 2 investors. Key investors include Korea Investment Holdings, and Hadasit.
What is Enlivex Pharmaceuticals's ticker symbol?
The ticker symbol of Enlivex Pharmaceuticals is ENLV on NASDAQ.